ACTA1 and muscular dystrophy: Since targeting the α-SMA gene expression has been advocated for inhibiting the myofibroblast differentiation to treat tissue fibrosis [31], it is important to understand whether myofibroblast is a significant player in the skeletal muscle fibrosis associated with DMD, and whether targeting α-SMA can be useful in treating the muscular dystrophy.